Pirfenidone regulates pericellular proteolysis in cancer
Dateien zu dieser Ressource
Datum
2022Autor
Krämer, Matthias
Betreuer/Gutachter
Wygrecka, Malgorzata
Fugmann, Tim
Zitierlink
http://dx.doi.org/10.22029/jlupub-5930Zusammenfassung
The orally available drug pirfenidone, which is approved for the therapy of idiopathic pulmonary fibrosis is inhibiting the proliferation and migration of lung cancer cells. This effects are partially mediated vie the regulation of the activity of the proteolytic system, especially via PAI-1.